Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,694 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
mRNA based vaccines provide broad protection against different SARS-CoV-2 variants of concern.
Wang H, Chen Z, Wang Z, Li J, Yan Z, Yuan J, Zhu A, Chen L, Liu Y, Hu C, Zhu A, Li G, Li Y, Deng J, Ma L, Sui X, Miao W, Li J, Zheng X, Piao J, Yao Y, Rao J, Shan C, Yuan Z, Zhao J, Zhu T. Wang H, et al. Among authors: zhu a, zhu t. Emerg Microbes Infect. 2022 Dec;11(1):1550-1553. doi: 10.1080/22221751.2022.2081616. Emerg Microbes Infect. 2022. PMID: 35604772 Free PMC article.
Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
Wu S, Huang J, Zhang Z, Wu J, Zhang J, Hu H, Zhu T, Zhang J, Luo L, Fan P, Wang B, Chen C, Chen Y, Song X, Wang Y, Si W, Sun T, Wang X, Hou L, Chen W. Wu S, et al. Among authors: zhu t. Lancet Infect Dis. 2021 Dec;21(12):1654-1664. doi: 10.1016/S1473-3099(21)00396-0. Epub 2021 Jul 26. Lancet Infect Dis. 2021. PMID: 34324836 Free PMC article. Clinical Trial.
Safety and Immunogenicity of a Recombinant Adenovirus Type-5-Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged ≥6 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial.
Zhu F, Jin P, Zhu T, Wang W, Ye H, Pan H, Hou L, Li J, Wang X, Wu S, Wang Y, Gou J, Huang H, Wu H, Wang X, Chen W. Zhu F, et al. Among authors: zhu t. Clin Infect Dis. 2022 Aug 24;75(1):e783-e791. doi: 10.1093/cid/ciab845. Clin Infect Dis. 2022. PMID: 34551104 Free PMC article. Clinical Trial.
Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients.
Yu Y, Wang M, Zhang X, Li S, Lu Q, Zeng H, Hou H, Li H, Zhang M, Jiang F, Wu J, Ding R, Zhou Z, Liu M, Si W, Zhu T, Li H, Ma J, Gu Y, She G, Li X, Zhang Y, Peng K, Huang W, Liu W, Wang Y. Yu Y, et al. Among authors: zhu t. Signal Transduct Target Ther. 2021 Sep 24;6(1):346. doi: 10.1038/s41392-021-00759-1. Signal Transduct Target Ther. 2021. PMID: 34561414 Free PMC article. Clinical Trial.
The nano delivery systems and applications of mRNA.
Li M, Li Y, Li S, Jia L, Wang H, Li M, Deng J, Zhu A, Ma L, Li W, Yu P, Zhu T. Li M, et al. Among authors: zhu a, zhu t. Eur J Med Chem. 2022 Jan 5;227:113910. doi: 10.1016/j.ejmech.2021.113910. Epub 2021 Oct 8. Eur J Med Chem. 2022. PMID: 34689071 Free PMC article. Review.
Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial.
Jin L, Tang R, Wu S, Guo X, Huang H, Hou L, Chen X, Zhu T, Gou J, Zhong J, Pan H, Cui L, Chen Y, Xia X, Feng J, Wang X, Zhao Q, Xu X, Li Z, Zhang X, Chen W, Li J, Zhu F. Jin L, et al. Among authors: zhu t, zhu f. Emerg Microbes Infect. 2023 Dec;12(1):2155251. doi: 10.1080/22221751.2022.2155251. Emerg Microbes Infect. 2023. PMID: 36503413 Free PMC article. Clinical Trial.
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial.
Wu JD, Li JX, Liu J, Wang HM, Zhou GH, Li J, Wu D, Chen X, Feng Y, Qi XY, Wang X, Gou JB, Ma TL, Yang XY, Xu LF, Wan P, Zhu T, Wang ZF, Zhu FC; CanSino COVID-19 Study Group. Wu JD, et al. Among authors: zhu t, zhu fc. Lancet Infect Dis. 2023 Sep;23(9):1020-1030. doi: 10.1016/S1473-3099(23)00199-8. Epub 2023 May 19. Lancet Infect Dis. 2023. PMID: 37216958 Clinical Trial.
7,694 results